The CEO of Nile AI spoke to how the newly founded company plans to develop data science techniques to improve the optimization of epilepsy care and management.
The movement disorder nurse practitioner at Stony Brook Medicine talked about the growing role of artificial intelligence in neurology and emerging treatments for Parkinson disease.
The neurologist and movement disorders fellow at University Hospitals Cleveland Medical Center spoke about the need for clinicians to have more time with patients in clinical practice, particularly with those with chronic diseases. [WATCH TIME: 2 minutes]
The medical director of the Stroke Center at Weill Cornell Medicine talked about results from a recent study on the risk of stroke in patients on assisted reproductive technologies during delivery hospitalization. [WATCH TIME: 4 minutes]
Panelists discuss how a multidisciplinary approach involving various specialists is crucial in managing generalized myasthenia gravis (gMG), offering final insights and recommendations for health care professionals treating gMG patients.
Closing their discussion on insomnia, panelists share final thoughts and advice for community physicians.
Steven Shapiro, MD, medical director for Stroke Services at RWJBarnabas Health’s Cooperman Barnabas Medical Center, highlighted some of the reasons why stroke occurs in younger adults under the age of 45 and the risk factors as well as preventative measures this population should be aware of.
The president and CEO at Alzheon shared recent insights into neurodegenerative diseases that suggest a single toxic trigger may be responsible for conditions like Alzheimer disease, leading to potential early intervention and treatment strategies. [WATCH TIME: 10 minutes]
Mary Ann Picone, MD, FAAN, FACP, provides a summary of her time at the recently held 2024 CMSC Annual Meeting.
Panelists look ahead in the management of advanced Parkinson disease and discuss the promise of different investigational therapies.
The professor in the Department of Translational Neuroscience at Barrow Neurological Institute provided perspective on the approval of tofersen (Qalsody; Biogen) for patients with ALS and the ways neurofilament light will be used going forward. [WATCH TIME: 3 minutes]
The professor and chair of the neurology department at the University of Arizonia, Phoenix, gave clinical insights on the notable progress in the stroke treatment world, highlighted by advances presented at the 2025 International Stroke Conference. [WATCH TIME: 3 minutes]
The assistant professor of neurology at University of Colorado School of Medicine discussed findings on the impact of cenobamate on hospital visits and emergency care for patients with drug-resistant epilepsy following surgery. [WATCH TIME: 3 minutes]
The postdoctoral fellow at the University of California San Diego discussed using CRISPR-based gene editing to alter the amyloid precursor protein gene in mice models with symptoms of Alzheimer disease. [WATCH TIME: 5 minutes]
The associate professor of clinical neurology at University of California, Irvine School of Medicine talked about addressing the critical unmet needs in disability progression among patients with multiple sclerosis. [WATCH TIME: 3 minutes]
Bijoy E. John, MD, founder and medical director of Sleep Wellness Clinics of America (Nashville) and Sleep Fix Academy, discussed the health risks associated with daylight saving time changes.
Mike Hennessy Sr, Chairman and founder, MJH Life Sciences™, offers his perspective on the questions around the origin of COVID-19 and applauds the extensive efforts to produce vaccines.
The associate professor at the North Carolina Agricultural and Technical State University provided insight on the widespread feasibility of a new initiative that aims to teach and attract young professionals to the MS field. [WATCH TIME: 4 minutes]
In the final episode, Negroski gave closing thoughts on some of the major unmet needs in research regarding aging in MS, as well as some of the unanswered questions clinicians are still trying to figure out.
The senior vice president and chief medical officer at Novartis Gene Therapies shared his perspective on the recent clinical trial results for Zolgensma in SMA type 1.
The professor of neurology at Northwestern University Feinberg School of Medicine discussed the NSD-ISS and its potential to refine PD diagnosis and clinical trial selection through biomarker-driven staging.
The undergraduate program director at the University of South Carolina discussed the shift in teaching strategies for those in neurology and why more hands-on experience serves students better. [WATCH TIME: 5 minutes]
Discussing adaptations to the comprehensive care model in multiple sclerosis, the founder of MS Bites commented on the need to consistently incorporate dietitians. [WATCH TIME: 6 minutes]
A panelist discusses how dual orexin receptor antagonists (DORAs), particularly daridorexant, are poised to become a first-line treatment for chronic insomnia, especially for elderly patients, due to their safety, tolerability, and lack of withdrawal symptoms, while highlighting the importance of patient education and regular follow-up for optimal results.
The director of the myasthenia gravis clinic at Yale University provided additional insight on the MINT study of inebilizumab in myasthenia gravis, some of the subanalyses within, and next plans in the drug’s development. [WATCH TIME: 5 minutes]
The medical student at Nova Southeastern University provided insight on a new innovative tool called the Cognitive Stress Test that can help distinguish different cognitive states for older adults. [WATCH TIME: 6 minutes]
The medical director of the Arkansas Children’s Comprehensive Epilepsy Program detailed advancements and strategies in using neuromodulation for LGS, as well as the future research needed to expand these approaches. [WATCH TIME: 4 minutes]
Despite previous data suggesting no link, the CDC and FDA will continue to review all evidence for possible increased risk of ischemic stroke.
Panelists discuss how physicians can improve outcomes for patients with chronic inflammatory demyelinating polyneuropathy (CIDP) by prioritizing early and accurate diagnosis, personalizing treatment plans, regularly monitoring patients, and addressing the psychological and emotional impact of the disease.